---
document_datetime: 2024-11-26 16:41:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/opsumit-epar-all-authorised-presentations_en.pdf
document_name: opsumit-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8107149
conversion_datetime: 2025-12-21 23:55:01.480817
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging         | Pack size                  |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------------|----------------------------|
| EU/1/13/893/001  | Opsumit           | 10 mg      | Film-coated tablet    | Oral use                  | blister (PVC/PE/PVdC/alu)   | 15 tablets                 |
| EU/1/13/893/002  | Opsumit           | 10 mg      | Film-coated tablet    | Oral use                  | blister (PVC/PE/PVdC/alu)   | 30 tablets                 |
| EU/1/13/893/004  | Opsumit           | 2.5 mg     | Dispersible tablet    | Oral use                  | blister (alu/desiccant/alu) | 30 x 1 tablets (unit dose) |